Blonanserin
ApprovedTerminated 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
First Episode Schizophrenia
Conditions
First Episode Schizophrenia, Social Function, Cognition Function, Blonanserin
Trial Timeline
Jan 22, 2019 โ Nov 22, 2022
NCT ID
NCT03784222About Blonanserin
Blonanserin is a approved stage product being developed by Sumitomo Pharma for First Episode Schizophrenia. The current trial status is terminated. This product is registered under clinical trial identifier NCT03784222. Target conditions include First Episode Schizophrenia, Social Function, Cognition Function.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03784222 | Approved | Terminated |
Competing Products
12 competing products in First Episode Schizophrenia